posted on 2018-07-27, 08:23authored bySusanne Schmitz, Áine Maguire, James Morris, Kai Ruggeri, Elisa Haller, Isla Kuhn, Joy Leahy, Natalia Homer, Ayesha Khan, Jack Bowden, Vanessa Buchanan, Michael O'Dwyer, Gordon Cook, Cathal Dominic Walsh
Background: Network meta-analysis (NMA) allows for the estimation of comparative effectiveness of treatments
that have not been studied in head-to-head trials; however, relative treatment effects for all interventions can only
be derived where available evidence forms a connected network. Head-to-head evidence is limited in many disease
areas, regularly resulting in disconnected evidence structures where a large number of treatments are available. This
is also the case in the evidence of treatments for relapsed or refractory multiple myeloma.
Methods: Randomised controlled trials (RCTs) identified in a systematic literature review form two disconnected
evidence networks. Standard Bayesian NMA models are fitted to obtain estimates of relative effects within each
network. Observational evidence was identified to fill the evidence gap. Single armed trials are matched to act as
each other’s control group based on a distance metric derived from covariate information. Uncertainty resulting
from including this evidence is incorporated by analysing the space of possible matches.
Results: Twenty five randomised controlled trials form two disconnected evidence networks; 12 single armed
observational studies are considered for bridging between the networks. Five matches are selected to bridge
between the networks. While significant variation in the ranking is observed, daratumumab in combination with
dexamethasone and either lenalidomide or bortezomib, as well as triple therapy of carfilzomib, ixazomib and
elozumatab, in combination with lenalidomide and dexamethasone, show the highest effects on progression free
survival, on average.
Conclusions: The analysis shows how observational data can be used to fill gaps in the existing networks of RCT
evidence; allowing for the indirect comparison of a large number of treatments, which could not be compared
otherwise. Additional uncertainty is accounted for by scenario analyses reducing the risk of over confidence in
interpretation of results.